TY - JOUR
T1 - Rate of Successful Extubation in Mechanically Ventilated Patients with Cirrhosis and Hepatic Coma
AU - Gibbs, Jeffrey T.
AU - Louissaint, Jeremy
AU - Tapper, Elliot B.
N1 - Funding Information:
Elliot Tapper receives funding from the National Institutes of Health through the NIDDK (1K23DK117055-01A1). Jeremy Louissaint received support through the T32DK062708.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022
Y1 - 2022
N2 - Background: The prognosis of critically ill patients with cirrhosis who require mechanical ventilation is guarded. Data are lacking for the optimal therapeutic approach to hepatic encephalopathy (HE) in the ventilated patient. Methods: Retrospective cohort analysis of 314 encounters (298 patients) with cirrhosis who underwent mechanical ventilation in a medical ICU and were ordered at least 1 dose of lactulose. Hazard of extubation alive was determined using a competing risk model. Primary exposures were HE therapy (lactulose and rifaximin) which were adjusted for the indication for ventilation (HE, procedures, respiratory failure), age, MELD-Na, and compensation status. Results: Indications for ventilation were 22.3% for grade 4 HE, 29.9% for procedures, and 47.8% for respiratory or cardiovascular failure. Median length of intubation was 2.63 days; death rate on ventilator was 31.2%. Relative to intubation for procedure, hazard of extubation for intubation for HE was 0.34 (95% confidence interval (CI): 0.22–0.52) and 0.33 (CI: 0.23–0.47) for respiratory failure. Hazard of extubation for rifaximin administration within 24-h after intubation was significant at 1.74 (1.21–2.50). Lactulose dosing was not significant for hazard of extubation. Discussion: Mortality is high for all patients with cirrhosis requiring mechanical ventilation, including those intubated for grade 4 HE. Efforts to optimize the odds of successful extubation are urgently needed. Our findings suggest improved incidence of extubation associated with rifaximin administration in the first 24-h after intubation. Prospective, multi-center data to confirm these findings in this vulnerable population are warranted.
AB - Background: The prognosis of critically ill patients with cirrhosis who require mechanical ventilation is guarded. Data are lacking for the optimal therapeutic approach to hepatic encephalopathy (HE) in the ventilated patient. Methods: Retrospective cohort analysis of 314 encounters (298 patients) with cirrhosis who underwent mechanical ventilation in a medical ICU and were ordered at least 1 dose of lactulose. Hazard of extubation alive was determined using a competing risk model. Primary exposures were HE therapy (lactulose and rifaximin) which were adjusted for the indication for ventilation (HE, procedures, respiratory failure), age, MELD-Na, and compensation status. Results: Indications for ventilation were 22.3% for grade 4 HE, 29.9% for procedures, and 47.8% for respiratory or cardiovascular failure. Median length of intubation was 2.63 days; death rate on ventilator was 31.2%. Relative to intubation for procedure, hazard of extubation for intubation for HE was 0.34 (95% confidence interval (CI): 0.22–0.52) and 0.33 (CI: 0.23–0.47) for respiratory failure. Hazard of extubation for rifaximin administration within 24-h after intubation was significant at 1.74 (1.21–2.50). Lactulose dosing was not significant for hazard of extubation. Discussion: Mortality is high for all patients with cirrhosis requiring mechanical ventilation, including those intubated for grade 4 HE. Efforts to optimize the odds of successful extubation are urgently needed. Our findings suggest improved incidence of extubation associated with rifaximin administration in the first 24-h after intubation. Prospective, multi-center data to confirm these findings in this vulnerable population are warranted.
KW - Hepatic encephalopathy
KW - Liver disease
KW - Mechanical ventilation
KW - Rifaximin
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=85124097321&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124097321&partnerID=8YFLogxK
U2 - 10.1007/s10620-022-07400-3
DO - 10.1007/s10620-022-07400-3
M3 - Article
C2 - 35107648
AN - SCOPUS:85124097321
SN - 0163-2116
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
ER -